Skip to content

IQVIA Holdings

US · IQV #493 by market cap Listed 1970
245.82 -4.73 -1.89%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

✦ Quant Fair Value how this is computed

Near fair value
185.58 fair value ≈ 260.13 334.68
  • Implied fair-value range of 185.58-334.68, from this stock's own trailing 5-year average P/E applied to trailing EPS.
  • Current price is -5.5% below the average-multiple fair value of 260.13.

Valuation each multiple against its own 5-year range

P/B ratio 6.08 In line with history 34th percentile
5-year average 6.35 · #28 of 41 in Diagnostics & Research
P/E ratio 29.91 In line with history 34th percentile
5-year average 33.18 · forward 27.62 · #7 of 20 in Diagnostics & Research
P/S ratio 2.34 Cheap vs history 28th percentile
5-year average 2.55 · forward 2.22 · #15 of 44 in Diagnostics & Research

Vs. peers Diagnostics & Research

Company Market cap P/E (TTM) P/B Div yield
IQVIA Holdings (IQV) 40.51B 29.91 6.08 0.00%
Thermo Fisher Scientific (TMO) 248.08B 35.31 4.53 0.27%
Danaher (DHR) 155.03B 36.12 2.89 0.69%
IDEXX Laboratories Inc (IDXX) 53.28B 45.57 28.50 0.00%
Agilent Technologies (A) 48.04B 33.61 6.52 0.59%
Waters (WAT) 43.29B 184.29 2.83 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★☆☆ Fair value258.65 Economic moatNarrow UncertaintyMedium

Trading 5.2% below Morningstar's fair value estimate.

Fair value

IQVIA Holdings Inc earns a 3-star quantitative star rating, reflecting our opinion that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 3% discount to our quantitative fair value estimate of $258.65 per share; however, some caution is warranted due to this estimate's medium uncertainty rating.

The company's balance sheet bolsters our quantitative valuation. Leverage can enable a company to invest in growth, potentially boosting shareholder value more than equity financing alone. For example, the firm's EBITDA/interest coverage ratio of 4.5 lies in the bottom 30% compared with peers globally. Although the firm's ability to cover interest payments with EBITDA is limited, shares could sharply rebound if economic circumstances change or recent investments reduce fears of default. We believe this is a sign that shares could be cheap.

Alternatively, the firm's valuation metrics are potentially concerning. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. The firm's book value yield of 15.2%, for example, lies in the bottom 20% globally. The market value of this company's shares looks expensive relative to the book (accounting) value of equity, which, despite our favorable price/fair value ratio, is a negative attribute.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. While we believe the stock is undervalued, this outperformance had a negative impact on our valuation estimate.

Economic moat

The narrow moat rating for this company indicates investors can expect it to generate 10 years or more of excess returns on capital due to its respectable competitive advantages. In addition, the company's moderate financial health score is decent and doesn't seriously concern us with regard to financial distress.

By Quantitative Equity Report

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

IQVIA Holdings discussion 0 comments

Add a comment